^
Association details:
Biomarker:IL6 elevation
Cancer:Melanoma
Drug:Yervoy (ipilimumab) (CTLA4 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: B - Late Trials
New
Title:

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition

Published date:
06/23/2020
Excerpt:
Analysis of baseline Checkmate-066 specimens showed that for nivolumab-treated patients, relatively high IL-6 was associated with poor OS with an adjusted HR of 1.63 (95% CI 1.04 to 2.55) (univariate HR of 2.43, 95% CI 1.60 to 3.70) and for dacarbazine-treated patients, IL-6 was associated with poor OS....demonstrated that for nivolumab-treated patients, IL-6 was associated with poor OS with an adjusted HR of 3.00 (95% CI 1.80 to 4.99) (univariate HR of 4.34, 95% CI 2.65 to 7.10). For ipilimumab-treated patients, IL-6 was associated with poor OS with an adjusted HR of 3.23 (95% CI 2.01 to 5.17) (univariate HR of 4.93, 95% CI 3.12 to 7.79).
Secondary therapy:
dacarbazine
DOI:
10.1136/jitc-2020-000842